Polymerase Chain Reaction Market to Surpass US$ 7.4 Billion by 2025

The Global Polymerase Chain Reaction Market, by Product Type (Instrument (Real Time PCR, Digital PCR, and Others) Reagents and Consumables)), by End User (Clinical Diagnostics, Academic and Research Laboratories, Forensic Laboratories, and Others), was valued US$ 3.7 billion in 2017 and is projected to exhibit a CAGR of 8.8%over the forecast period (2017 – 2025) as highlighted in a new report published by Coherent Market Insights.

Polymerase chain reaction (PCR) is laboratory technique used to amplify a single copy or a few copies of DNA segment to make several thousand to millions of copies of a particular DNA sequence. PCR has extensive applications in various fields, which includes diagnosis of infectious diseases, such as middle ear infections, tuberculosis, Lyme disease, DNA fingerprinting, paternity testing and in various other molecular research applications, such as DNA sequencing, DNA cloning, and gene expression.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1546

Moreover, increasing prevalence and incidence of infectious and chronic disease coupled with increasing need to develop advanced polymerase chain reaction system to deliver rapid and inexpensive quantitative detection of target sample, are the major factors driving growth of global polymerase chain reaction market over the forecast period. Digital PCR (dPCR) is a new approach to nucleic acid detection and quantification. Digital PCR provides ultrasensitive and absolute nucleic acid quantification. dPCR is particularly used in rare allele detection and for absolute quantification of gene expression and viral load. Moreover, advancement in the dPCR leads to the introduction of droplet digital PCR (ddPCR). ddPCR is method of performing digital PCR, using water-oil emulsion droplet technology. In ddPCR technology sample is fractionated into 20,000 droplets, and PCR amplification of the template molecules occurs in each individual droplet, then by counting the positive droplets provides precise and absolute target quantification. ddPCR technology uses reagents and workflows, similar to those used for most standard probe-based assays.

Browse 28 Market Data Tables and 34 Figures spread through 150 Pages and in-depth TOC on "Polymerase Chain Reaction Market, by Product Type (Instrument (Real Time PCR, Digital PCR, Others) Reagents and Consumables)), by End User (Clinical Diagnostics, Academic and Research Laboratories, Forensic Laboratories, Others) - Global Forecast to 2025"

Continuous research and development and technology advancements in polymerase chain reaction system allows to introduce the better and affordable instruments, reagent and consumables in the field of clinical diagnosis. For instance, in March 2018, Sekisui Diagnostics launched Silaris Influenza A&B Test: an affordable, polymerase chain reaction (PCR) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis. In October 2017, Diatech Pharmacogenetics srl launched easyPGX: a ready to use in-vitro diagnostic real-time PCR product line and Helix: a polymerase chain reaction kit for the extraction of circulating free DNA from plasma.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1546

Moreover, in September 2015, Bio-Rad Laboratories launched droplet digital PCR (ddPCR) Supermix for Residual DNA Quantification. The new supermix designed to use with Bio-Rad’s Droplet Digital PCR Systems, and allows highly precise and sensitive method for DNA measurement. In November 2014, Chai Biotechnologies Inc. introduced Open qPCR: Real-Time PCR Thermocycler. The new instrument is designed to for genetic genotyping, pathogen detection, and relative DNA quantification. Moreover, In April 2014, Bio-Rad Laboratories launched Precision Blue Real-Time PCR Dye. The new Precision Blue dye is compatible with Bio-Rad’s universal qPCR supermixes, and can be used with all Bio-Rad’s CFx real time PCR systems. In November 2012, Life Technologies Corporation launched its Applied Biosystems QuantStudio Dx Real-Time PCR Instrument, in Europe. The new PCR instrument is designed to be used in the clinical diagnostic laboratory tests such as pathogen detection, gene expression analysis, SNP genotyping, mutation detection, micro-RNA and other non-coding RNA analysis.

Key takeaways of the polymerase chain reaction market:

The global polymerase chain reaction market is expected to expand at a CAGR of 8.8% during the forecast period (2017 – 2025), owing to increasing prevalence of chronic and infectious disease and growing demand for continuous technology advancement in polymerase chain reaction from highly lucrative market especially in Asia Pacific, Latin America, Middle East, and Africa.

Reagents and consumables hold major market share in product type segment, owing to its inevitable need in PCR instruments to run the sample and amplify the target DNA sequence.

Among end user, academic and research laboratories hold largest market share, owing to the increasing need of polymerase chain reaction (PCR) system in advanced laboratory testing and research services.

Some of the major players involved in global polymerase chain reaction market include F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux, S.A., Enzo Life Science, Inc., Abbott Laboratories, Takara Bio Inc., Becton, Dickinson and Company, and Danaher Corporation.

To know the latest trends and insights related to polymerase chain reaction market, click the link below: https://www.coherentmarketinsights.com/market-insight/polymerase-chain-reaction-market-1546

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.